Salute e Benessere

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and…

- Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma -Second doses of intravenous VCN-01 administered to patients in Spain and were well tolerated with a safety profile consistent with prior clinical trials - -VIRAGE remains on track to complete enrollment in the first quarter of 2024-- VCN-01 granted Orphan Drug Designation by the U.S. FDA for the treatment of pancreatic cancer – ...

LifeSci Consulting Expands with Global Operations Consulting Capability and…

“Nick and his team have shown a consistent ability throughout their careers to advise senior life science leaders in developing strategies and orchestrating diverse capabilities to implement tangible change – be that transforming enterprise cost bases, restructuring organizations, or implementing complex outsourcing solutions,” said Jason Laffin, Managing Partner of LifeSci Consulting. “This is a significant investment in the growth of our consulting business – both establishing a presence...

Calyx RIM Successfully Implemented by a Global Market Leading Pharmaceutical…

eCTD 4.0 is a standard format for submitting applications, amendments, supplements, and reports to FDA's Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER). eCTD 4.0 submission pilots that enable select pharmaceutical companies to evaluate their eCTD 4.0 readiness are being conducted by multiple worldwide regulatory agencies and are crucial to the success of both industry and health authorities alike. eCTD 4.0 is a standard format for...

ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS

(in thousands, except per share amounts) (in thousands, except per share amounts) CONSOLIDATED FINANCIAL RESULTS Total revenues were$547 millionin second-quarter 2023, a decrease of 4% compared to$569 millionin second-quarter 2022. This decrease was primarily attributable to decreased revenues from the Generic Pharmaceuticals segment. Reported income from continuing operations in second-quarter 2023 was$24 millioncompared to reported loss from continuing operations of...

Tecan schedules conference call on August 15th to discuss half year 2023…

Männedorf, Switzerland, August 8, 2023 –The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to discuss the financial results for the first half year 2023 on Tuesday, August 15th, 2023 at 09:00 CEST. The results will be published on August 15th, 2023 at 6:00 CEST. The conference call will be audio-webcast with synchronized presentation slides. The webcast and a replay of the webcast will be made available in the "Investor Relations" section of Tecan's website…

Race Strategic Update August 2023

Race's new strategy has been designed to maximise the inherent value of bisantrene: Race's new strategy has been designed to maximise the inherent value of bisantrene: Anti-cancer + cardio-protection Race's core focus is to impact cancer outcomes and address the challenges of chemotherapeutic cardiotoxicity. Studies will leverage the unique mechanisms of bisantrene in mBC and AML, both cancer patient populations with a high unmet need, paving the way to a host of future indications...

iTeos Reports Second Quarter 2023 Financial Results and Provides Business…

– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination – Initiated enrollment in Phase 1 trial of EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway– Cash balance and investment balance of $677.5 million as of June 30, 2023 expected to provide runway into 2026 through a number of impactful milestones across portfolio WATERTOWN, Mass. and GOSSELIES, Belgium, Aug.08, 2023...

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides…

2Q 2023 ZYNLONTA ®1net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20% 2year-over-yeardue to portfolio prioritization and organizational efficienciesPipeline advancing with initial data readouts from the clinical trials of LOTIS-7, ADCT-601 targeting AXL and ADCT-901 targeting KAAG1 expected in 2024Company to host conference call today at 8:30 a.m. EDTLAUSANNE,...

Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse…

Bagsværd, Denmark , 8 August 2023– Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The double-blinded trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular events (MACEs) over a period of up to five years. The trial enrolled 17,604 adults aged 45 years or older with overweight or obesity and established cardiovascular disease (CVD) with no...

ALPINION Launches a High-Performance Portable Ultrasound Diagnostic Device…

In particular, the X-CUBE i9 was praised for excellent high-quality images by the Radiological Society of North America at the end of last year and Arab Health earlier this year. The X+ Architecture used in advanced models is built in the X-CUBE i9 to express high-resolution images, high frame rate, and rich color of cart device level. Applying the X+ Crystal Signature transducer, which minimizes noise by advancing the existing Single Crystal transducer technology, improved diagnostic…

Brainomix AI Technology Improves Access to Stroke Treatment across the NHS

Many stroke patients in the UK who could benefit from mechanical thrombectomy do not receive it. This specialist procedure is done by interventional neuroradiology teams located in only 25 of the 170 acute hospitals across England. Most patients with a suspected stroke are first assessed at their local hospital A&E, so patients who might benefit from thrombectomy need to be quickly identified and transferred to a specialist centre before irreversible brain injury has occurred. Identifying…

STORM Therapeutics publishes data in Cancer Discovery showing induction of…

CAMBRIDGE, England, Aug. 8, 2023 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it has published a scientific manuscript in the internationally recognised scientific journal Cancer Discovery. CAMBRIDGE, England,Aug. 8, 2023/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), a clinical...

Nasus Pharma Announces Publication Of Its Positive Clinical Results With…

FMXIN002 is an investigational intranasal epinephrine powder spray device that is noninvasive, user-friendly and reliable and could provide timely effective rescue for severe potentially life-threatening allergic reactions to food, medications and insect bites. The clinical study provides additional compelling evidence to the robustness of Nasus Pharma's intranasal powder technology already tested in other drugs. Importantly the pharmacokinetics of the powder-based intranasal epinephrine can…

Safe Orthopaedics announces the publication of a biomechanical study on Sycamore

Safe Orthopaedics announces the publication of a biomechanical studyonSycamorePublication in theJournal of Experimental Orthopaedicsof the results of the Sycamore biomechanical studyOver 160 patients treated with Sycamore Éragny-sur-Oise, Fleurieux sur l'Arbresle , France, le 07 août 2023 à 17h30 CET –Safe (FR001400F1V2 – ALSAF), french group specialized in the design, manufacturing and distribution of ready-to-use...

Bactolife Raises EUR 30 million in Series A Financing

Sebastian Søderberg, CEO of Bactolife said: "We are very pleased and humbled by the continued confidence that investors have shown us, especially in times of geopolitical uncertainty and market turmoil. The funding allows us to increase our investments in our project pipeline, technology platform, organisation and upscaling capabilities. Further, it will enable Bactolife to accelerate our partnering efforts with world-leading companies and commercialise our first product concepts for humans…

India Stainless Steel HRC and CRC Coils Market, 2023 Insights Forecast CAGR of…

Get research insights in detail: https://www.marketdecipher.com/report/india-hot-rolled-coil-steel-market-report Get research insights in detail:https://www.marketdecipher.com/report/india-hot-rolled-coil-steel-market-report " In fiscal year 2022-23, the demand for domestic steel amounted to 132.74 million metric tons. It is anticipated that this demand will experience a 7.2% increase, reaching a total of 163.85 million metric tons in the subsequent financial year, 2024-25. The India...

Mithra and Gedeon Richter Sign Supply Agreement for Production of API for…

Mithra and Gedeon Richter Sign Supply Agreement for Production of API forEstelle ®and Donesta ®Gedeon Richter will manufacture and supply Estetrol (E4) for production of Estelle® , Donesta®Strengthens Mithra'ssupplychainwith commercially attractive source for Estetrol Liege, Belgium and Budapest, Hungary8August 2023– 07:30 CEST– Mithra (Euronext Brussels: MITRA), a company dedicated to Women's...

SYSNAV Healthcare Announces EMA Primary Endpoint Qualification of Stride…

VERNON, France, Aug. 8, 2023 /PRNewswire/ -- SYSNAV Healthcare announces that the European Medicines Agency (EMA) considers that for ambulant Duchenne Muscular Dystrophy (DMD) patients four years of age and above, Stride Velocity 95th centile (SV95C) qualifies as primary endpoint in superiority studies as an alternative to the 6 Minute Walking Test (also called 6 Minute Walking Distance) provided this outcome measure is supported by consistent findings in established efficacy endpoints included…

First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in…

IPAX-2 is being conducted at six sites across Australia, New Zealand and Europe. The study will build on data generated in IPAX-1 (ClinicalTrials.gov Identifier NCT03849105), which reported final results in September 2022.[1] The IPAX-1 study met its primary objective demonstrating safety and tolerability profile of intravenous 131I-IPA administered concurrently with second line EBRT. The study also delivered encouraging preliminary therapeutic effect, demonstrating a median overall survival of…

Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses…

Key Takeaways from the Bladder Cancer Market Report Key Takeaways from the Bladder Cancer Market Report Discover which therapies are expected to grab the major bladder cancer market share @Bladder Cancer Market Report Bladder Cancer Overview Bladder cancer is a prevalent form of cancer that develops in the tissues of the bladder, the organ responsible for storing urine. It is more commonly found in older individuals, particularly those over the age of 55, and is more...

Cellectis Provides Full Report for Second Quarter 2023 Financial Results

Financial Results The interim condensed consolidated financial statements of Cellectis, have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”).We present certain financial metrics broken out between our two reportable segments – Therapeutics and Plants – in the appendices of this Q2 2023 financial results press release.On January 13, 2023, Calyxt, Cibus Global LLC (Cibus) and certain other...

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 8convertible bonds in Oxurion resulting in a EUR 200 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – August7 , 2023 – 7 .00PM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on August...

Disposable Gloves Market Size to Grow USD 15830 Million by 2029 at a CAGR of…

Major Factors Driving the Growth of the Disposable Gloves Market: Major Factors Driving the Growth of the Disposable Gloves Market : Growing public knowledge of illnesses linked to healthcare will likely fuel industry expansion. The healthcare industry is expected to expand significantly in major emerging economies due to a number of factors, including rising investments in both the public and private sectors, population expansion, a large intake of migrants, and an increasing geriatric...

Altri Comunicati